Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multipotency of Hematopoietic Stem Cells

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Identification of key substances and mechanisms of action for the pleasurable aroma of Shaoxing Huangjiu based on GC-MS, molecular docking, and sensory evaluation.

Food chemistry·2026

Same author

Benzo[a]pyrene carcinogenicity across organs and cancer stages: Molecular mechanisms and interactions with co-exposed chemicals.

Environmental pollution (Barking, Essex : 1987)·2026

Same author

Lichang decoction suppresses AOM+DSS-induced colitis-associated cancer via regulating intestinal flora and suppressing the Wnt/β-catenin signaling pathway.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026

Same author

Hypertension management profiles in Chinese adults aged 60 years and older.

Frontiers in public health·2026

Same author

Molecular level analysis of aroma differences between Huangjiu and beer: Insights from concentration balancing and sensory models.

Food chemistry·2026

Same author

Pore-Space-Partitioned Metal-Organic Frameworks with Acyclic Diene Linkers for C<sub>2</sub>H<sub>2</sub>/CO<sub>2</sub> Separation.

Inorganic chemistry·2026

Search research articles

Related Experiment Video

Updated: Apr 27, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Distinguishing CML LSCs from HSCs using CD26.

Xiaoyan Jiang¹

¹British Columbia Cancer Agency; University of British Columbia.

|June 21, 2014

Summary

Researchers identified CD26 as a specific biomarker for chronic myeloid leukemia (CML) stem cells. This finding helps distinguish leukemic stem cells (LSCs) from normal hematopoietic stem cells (HSCs) and offers a potential therapeutic target.

Area of Science:

Hematology
Cancer Biology
Stem Cell Research

Background:

Chronic myeloid leukemia (CML) is a stem cell-driven malignancy.
Distinguishing leukemic stem cells (LSCs) from normal hematopoietic stem cells (HSCs) is crucial for effective CML therapy.
Identifying specific biomarkers for LSCs is an ongoing research priority.

Purpose of the Study:

To identify a specific biomarker for CML stem cells.
To phenotypically differentiate LSCs from HSCs.
To explore the therapeutic potential of this biomarker in CML.

Main Methods:

Utilized phenotypic analysis to characterize stem cell populations in CML.
Investigated the expression of CD26 on LSCs and HSCs.
Assessed the potential of CD26 as a therapeutic target.

More Related Videos

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Related Experiment Videos

Last Updated: Apr 27, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

Published on: February 21, 2021

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Main Results:

CD26 was demonstrated to be a novel and specific biomarker for CML stem cells.
CD26 expression effectively distinguishes LSCs from normal HSCs.
CD26 emerged as a promising therapeutic target for CML treatment.

Conclusions:

CD26 is a valuable biomarker for identifying and isolating CML stem cells.
Targeting CD26 may offer a new therapeutic strategy for CML patients.
This discovery advances our understanding of CML stem cell biology and treatment.